AMGN Stock Chart & Stats
$7580.50
$0.00(0.00%)
At close: 4:00 PM EDT
$7580.50
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4,300.00 - $7,769.00
Previous CloseN/A
Volume0.00
Average Volume (3M)38.00
Market Cap
$3.46T
Enterprise Value$240.31K
Total Cash (Recent Filing)$13.99B
Total Debt (Recent Filing)$57.30B
Price to Earnings (P/E)23.3
Beta-0.24
Next Earnings
Nov 03, 2026EPS Estimate
98.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.22
Shares Outstanding540,632,000
10 Day Avg. Volume0
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6,751.03Price Target Upside-10.94% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering24
EPS Forecast (FY)392.2
Revenue Forecast (FY)$662.10B
Bulls Say, Bears Say
Bulls Say
Diversified Commercial GrowthGrowth is spread across several important products rather than concentrated in a single therapy, reducing dependence on one asset. Broad expansion across cardiovascular, rare disease, oncology, inflammation and biosimilars supports a more resilient revenue base over the next several quarters.
Strong Profitability And Cash GenerationHigh margins and substantial free cash flow demonstrate strong earnings quality and the economic strength of Amgen’s biologics portfolio. Cash generation can fund research, manufacturing expansion, dividends and business development while providing capacity to address its debt burden.
Validated Pipeline ExpansionPositive Phase 3 evidence for Imdelltra in an earlier treatment setting could expand the medicine’s addressable market and extend its commercial life. A demonstrated survival benefit also strengthens Amgen’s development track record and supports future portfolio growth.
Bears Say
High Balance-sheet LeverageAmgen’s sizable debt relative to equity reduces financial flexibility and increases sensitivity to refinancing costs or weaker earnings. Although leverage has improved from prior years, the capital structure remains more burdened than typical and may constrain allocation choices.
Biosimilar Pressure On Prolia And XGEVAThe decline shows that biosimilar competition can materially erode established franchises, creating a durable headwind for revenue and earnings. Continued pressure on these products places greater importance on newer growth assets to offset lost contribution from mature therapies.
Pipeline Execution UncertaintyStopped or inconclusive development programs highlight the scientific and execution risk inherent in Amgen’s pipeline. While other assets are advancing, failed studies can reduce future growth options, increase development costs and make replacement of declining products less predictable.
Amgen News
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $4300.00 and its highest was $7769.00 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $3.46T.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Nov 03, 2026 which is in 51 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Aug 04, 2026. The company reported $106.778 earnings per share for the quarter, beating the consensus estimate of $95.354 by $11.425.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Overvalued.
Does Amgen pay dividends?
Amgen does not currently pay dividends.
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 98.22.
How many shares outstanding does Amgen have?
Amgen has 540,632,000 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $106.778 in its last earnings report, beating expectations of $95.354. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in MX:AMGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6,751.03 (-10.94% Downside)
$6,751.03 (-10.94% Downside)
Blogger Sentiment
Bullish
MX:AMGN Sentiment 60%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $13.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 69%
Bearish news 31%
Bearish news 31%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.16%
12-Months-Change
Fundamentals
Return on Equity
2.58%
Trailing 12-Months
Asset Growth
8.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Amgen
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
AMGN Company Deck
AMGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported broad-based commercial strength (10% revenue growth, multiple products with double-digit increases, raised full-year guidance), robust margins (48% non-GAAP operating margin) and strong cash generation, while also flagging expected near-term expense increases, higher cost-of-sales pressure from mix and profit-share, a material decline in the Prolia/XGEVA franchise (–33%), and some pipeline uncertainty/readouts pending. On balance the positive commercial execution, raised guidance and pipeline momentum outweigh the noted headwinds.View all MX:AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$6,751.03
▼(-10.94% Downside)